Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Chevron

Travelers

It hasn't taken huge returns to rank among the top three of the Dow this year.

3 Best Dow Jones Stocks of 2022 So Far: Are They Buys Now?

Amgen

CRISPR Therapeutics

Exelixis

iShares Nasdaq Biotechnology ETF

Ionis Pharma

Twist Bioscience Corp

I've written before about how biotech is the biggest technology trend of our kids' generation. Naturally, that means many people are looking for the best biotech stocks to buy.

The 7 Best Biotech Stocks to Buy

General Mills

Kraft Heinz

Coca-Cola

Kroger

Lockheed Martin

McDonald's

Some on Wall Street feel that technical stock analysis is the key to finding directions and market trends.

7 ‘Strong Buy' Defensive Dividend Stocks to Grab Now as Markets May Return to June Lows

Merck MRK, -1.23% said Tuesday it is launching a new Phase 3 trial of once-daily islatravir for the treatment of people with HIV-1 infection. "These new Phase 3 studies will evaluate a once-daily oral combination of doravirine 100 mg and a lower dose of islatravir (DOR/ISL)," the company said in a statement.

Merck launches new Phase 3 trial of once-daily HIV treatment, to discontinue trial of once-monthly dose

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Start New Ph 3 Clinical Program with Lower Dose of Daily Oral Islatravir in Combination with Doravirine for Treatment of People with HIV-1

Merck to Initiate New Phase 3 Clinical Program with Lower Dose of Daily Oral Islatravir in Combination with Doravirine for Treatment of People with HIV-1 Infection

The EMA's CHMP recommends approving Merck's (MRK) pneumococcal 15-valent conjugate vaccine for expanded use in infants and children. The vaccine received similar approval from the FDA in June 2022.

Merck's (MRK) Pneumococcal Jab Gets CHMP Endorsement for Kids

BHP Billiton

Citigroup

General Motors

Micron Technology

Northrop Grumman

Vale S.A.

Although the tail end of the third quarter brought some unwanted volatility to the market, forward-thinking investors might want to use this time to strategize undervalued stock picks. One of the primary benefits of this approach is that such securities may not have that much further to correct.

7 Undervalued Stock Picks to Beat the September Market Slump

AbbVie

AstraZeneca

Novartis

Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, AbbVie (ABBV), Novartis (NVS), Merck (MRK) and AstraZeneca (AZN) are worth retaining in your portfolio.

4 Large Drug Stocks to Watch as Fundamentals Stay Strong

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Receives Positive CHMP Opinion for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Infants and Children

Merck Receives Positive CHMP Opinion for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Infants and Children

Archer-Daniels-Midland Company

Coterra Energy

Are you spooked because the S&P 500 is off 16.26% going into Thursday? If you are, then check out Hartford Equity Income Fund.

Fund Tops Market With Higher Income, Low Volatility Strategy

Strong sales of its top blockbuster overcome some weaker pipeline results.

Why This Monster Stock's Recent Blunders Might Not Matter

Strong sales of key products like Keytruda and Gardasil, a significant contribution from Lagevrio and positive pipeline/regulatory developments have been keeping Merck's (MRK) stock afloat in 2022.

Key Factors Driving Merck's (MRK) Outperformance This Year

According to a Berenberg bull note, Merck & Co., Inc. (NYSE:MRK) is a solid "low-risk value option" in the pharmaceutical sector.

Analyst: Merck Stock is a "Low-Risk Value Option"

DTE Energy

NextEra Energy

PepsiCo

Republic Services

Raytheon Technologies

Constellation Brands

September is the worst month of the year for stocks, but the real scary month this year could be October, and not just because of the potential for a spooky Halloween.

Goldman Sachs Says Beware of Dangerous Fall Market Volatility: 7 Safe Conviction List Dividend Stocks to Buy Now

Magellan Midstream Partners

2022 is the 11th most volatile year in US history with stocks crashing and rocketing upwards. Whether stocks have already bottomed or have as much as 30% more to fall is an open question hotly debated by economists and SA readers alike.

2 Perfect High-Yield Blue-Chips For This Volatile Market

Merck & Co., Inc. (NYSE:MRK ) Morgan Stanley 20th Annual Global Healthcare Conference September 12, 2022 2:15 PM ET Company Participants Rob Davis - Chief Executive Officer Dean Li - Head of R&D Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Okay. Great. Thanks for joining us, everybody.

Merck & Co., Inc. (MRK) Presents at Morgan Stanley 20th Annual Global Healthcare Conference (Transcript)

Seagen

BOTHELL, Wash. & TOKYO & RAHWAY, N.J.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN), Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the phase 1b/2 EV-103 clinical trial (also known as KEYNOTE-869) Cohort K investigating PADCEV® (enfortumab vedotin-ejfv) in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) and PADCEV alone as first-line

Seagen, Astellas and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer

– Results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab –  – Data highlighted in late-breaking presentation at the European Society for Medical Oncology (ESMO) Congress 2022 – TOKYO and BOTHELL, Wash. and RAHWAY, N.J.

Astellas, Seagen and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer

A gamble could pay off for Merck stock after blockbuster Keytruda nearly doubled the five-year survival rate for some lung cancer patients. The post Merck Gambled With Keytruda In 2011 — How That Jump Is Still Paying Off Today appeared first on Investor's Business Daily.

Merck Gambled With Keytruda In 2011 — How That Jump Is Still Paying Off Today

RAHWAY, N.J.--(BUSINESS WIRE)--Five-Year Data for Merck's KEYTRUDA Plus Chemotherapy Showed Sustained Survival Benefit Versus Chemotherapy Alone in Two Studies for Metastatic NSCLC

Five-Year Data for Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Sustained Survival Benefit Versus Chemotherapy Alone in Two Studies for Metastatic Non-Small Cell Lung Cancer (NSCLC)

RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)--Merck and Eisai Present Results From Phase 3 LEAP-002 Trial Evaluating KEYTRUDA Plus LENVIMA Versus LENVIMA Monotherapy in Patients With uHCC

Merck and Eisai Present Results From Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--AstraZeneca and Merck, known as MSD outside of the United States and Canada, today announced long-term follow-up results from the Phase 3 PAOLA-1 and SOLO-1 trials in first-line advanced ovarian cancer, which represent the longest-term data for any PARP inhibitor in this setting. These results were presented on Sept. 9 at the European Society for Medical Oncology (ESMO) 2022 Congress, and the SOLO-1 results were published in the Journal of Clinical Oncology. Ovari

LYNPARZA® (olaparib) in Combination With Bevacizumab, and as Monotherapy, Demonstrates Clinically Meaningful Long-Term Survival in Certain Patients With First-Line Advanced Ovarian Cancer in Exploratory Analyses of Two Phase 3 Trials

NRG Energy

Walmart

Cheniere Energy

The wind behind the bear market summer rally was driven by a belief by many that the Federal Reserve was getting close to a pivot on rate policy.

Goldman Sachs Says Next Fed Rate Increases Will Be Big: 7 Conviction List Dividend Stocks to Buy Now

There is more to the comparison, and in the sections below, we discuss why we believe MRK stock will offer better returns than PFE stock in the next three years.

Pfizer's Peer Appears To Be A Better Pharmaceuticals Pick

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--The Merck Foundation (the Foundation) announced today the launch of the Alliance for Equity in Cancer Care (the Alliance), a $20 million, five-year initiative, designed to make cancer care more equitable in the United States by helping patients living in underserved communities receive timely access to high-quality, culturally responsive care. “The severity of the need to take action on advancing equity in cancer care cannot be overstated and will not be overlooke

News for Merck Stock (MRK)